Detalhe da pesquisa
1.
A road map to evaluate the proteome-wide selectivity of covalent kinase inhibitors.
Nat Chem Biol
; 10(9): 760-767, 2014 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-25038787
2.
N-(Pyridin-2-yl) arylsulfonamide inhibitors of 11ß-hydroxysteroid dehydrogenase type 1: strategies to eliminate reactive metabolites.
Bioorg Med Chem Lett
; 23(8): 2344-8, 2013 Apr 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-23489629
3.
Pyrimidone-based series of glucokinase activators with alternative donor-acceptor motif.
Bioorg Med Chem Lett
; 23(16): 4571-8, 2013 Aug 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-23831135
4.
Direct control of CAR T cells through small molecule-regulated antibodies.
Nat Commun
; 12(1): 710, 2021 01 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-33514714
5.
N-(Pyridin-2-yl) arylsulfonamide inhibitors of 11beta-hydroxysteroid dehydrogenase type 1: Discovery of PF-915275.
Bioorg Med Chem Lett
; 19(13): 3493-7, 2009 Jul 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-19473839
6.
A strategy for risk management of drug-induced phospholipidosis.
Toxicol Pathol
; 37(7): 997-1005, 2009 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-20008549
7.
Protein tyrosine phosphatase 1B inhibitors for diabetes.
Nat Rev Drug Discov
; 1(9): 696-709, 2002 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-12209150
8.
Discovery of N-((3R,4R)-4-Fluoro-1-(6-((3-methoxy-1-methyl-1H-pyrazol-4-yl)amino)-9-methyl-9H-purin-2-yl)pyrrolidine-3-yl)acrylamide (PF-06747775) through Structure-Based Drug Design: A High Affinity Irreversible Inhibitor Targeting Oncogenic EGFR Mutants with Selectivity over Wild-Type EGFR.
J Med Chem
; 60(7): 3002-3019, 2017 04 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-28287730
9.
Structure-based design of a parallel synthetic array directed toward the discovery of irreversible inhibitors of human rhinovirus 3C protease.
J Med Chem
; 45(10): 2016-23, 2002 May 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-11985469
10.
Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 8. Pharmacological optimization of orally bioavailable 2-pyridone-containing peptidomimetics.
J Med Chem
; 46(21): 4572-85, 2003 Oct 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-14521419
11.
Evaluation of a published in silico model and construction of a novel Bayesian model for predicting phospholipidosis inducing potential.
J Chem Inf Model
; 47(3): 1196-205, 2007.
Artigo
em Inglês
| MEDLINE | ID: mdl-17428028
12.
Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. Part 7: structure-activity studies of bicyclic 2-pyridone-containing peptidomimetics.
Bioorg Med Chem Lett
; 12(5): 733-8, 2002 Mar 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-11858991